A testsúlycsökkentés hatása a kombinált interferon-alfa-2a + ribavirin kezelésre adott válaszra idült HCV-hepatitisben

Translated title of the contribution: The effect of body weight reduction on the effectivity of combined peginterferon and ribavirin treatment in chronic HCV hepatitis

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

The overweight/obesity is an independent negative predictive factor of steatosis in chronic hepatitis C virus infection. The nonresponse to combined peginterferon and ribavirin treatment in infection caused by genotype 1 is associated with the waist circumference, body mass index (BMI), diabetes, steatosis, and degree of fibrosis. The obesity is an independent negative predictive factor of inefficacy of antiviral treatment. Case report: The authors summarize the case of a 59-year-old obese (BMI = 46.47 kg/m2) male patient with chronic HCV infection. The weight reduction - after two ineffective antiviral treatments - helped the biochemical and virological response to combined peginterferon-alpha-2a and ribavirin treatment. Between the combined peginterferon and ribavirin therapy, the patient was treated with amantadine and silymarin. Discussion: The authors summarize the importance of steatosis and insulin resistance in chronic HCV hepatitis as well as review the impact of weight reduction and the improvement of insulin sensitivity. Conclusion: Body-weight reduction and hepatoprotective drug might have increased the effectivity of combined peginterferon and ribavirin treatment and thus the sustained virological respond.

Translated title of the contributionThe effect of body weight reduction on the effectivity of combined peginterferon and ribavirin treatment in chronic HCV hepatitis
Original languageHungarian
Pages (from-to)2189-2192
Number of pages4
JournalOrvosi hetilap
Volume149
Issue number46
DOIs
Publication statusPublished - Nov 16 2008

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint Dive into the research topics of 'The effect of body weight reduction on the effectivity of combined peginterferon and ribavirin treatment in chronic HCV hepatitis'. Together they form a unique fingerprint.

  • Cite this